Literature DB >> 22847102

Timing and location of blood product transfusion and outcomes in massively transfused combat casualties.

Andrew P Cap1, Philip C Spinella, Matthew A Borgman, Lorne H Blackbourne, Jeremy G Perkins.   

Abstract

BACKGROUND: Hemostatic resuscitation using blood components in a 1:1:1 ratio of platelets:fresh frozen plasma:red blood cells (RBCs) is based on analyses of massive transfusion (MT, ≥10 RBC units in 24 hours). These 24-hour analyses are weakened by survival bias and do not describe the timing and location of transfusions. Mortality outcomes associated with early (first 6 hours) resuscitation incorporating platelets, for combat casualties requiring MT, have not been reported.
METHODS: We analyzed records for 8,618 casualties treated at the United States military hospital in Baghdad, Iraq, between January 2004 and December 2006. Patients (n = 414) requiring MT, not receiving fresh whole blood, and surviving at least 1 hour (reducing survival bias) were divided into 6-hour apheresis platelet (aPLT) transfusion ratio groups: LOW (aPLT:RBC, ≤0.1, n = 344) and HIGH (aPLT:RBC, >0.1, n = 70). Baseline characteristics of groups were compared. Factors influencing survival on univariate analysis were included in Cox proportional hazards models of 24-hour and 30-day survival.
RESULTS: Patients received aPLT in the emergency department (4%), operating room (45%), intensive care unit (51%). The HIGH group presented with higher (p < 0.05) admission International Normalized Ratio (1.6 vs. 1.4), base deficit (8 vs. 7), and temperature (36.7 vs. 36.4). Overall mortality was 27%. At 24 hours, the HIGH group showed lower mortality (10.0% vs. 22.1%, p = 0.02). Absolute differences in 30-day mortality were not significant (HIGH, 18.6%; LOW, 28.8%, p = 0.08). On adjusted analysis, the HIGH group was independently associated with increased survival: LOW group mortality hazard ratios were 4.1 at 24 hours and 2.3 at 30 days compared with HIGH group (p = 0.03 for both). Increasing 6-hour FFP:RBC ratio was also independently associated with increased survival.
CONCLUSION: Early (first 6 hours) hemostatic resuscitation incorporating platelets and plasma is associated with improved 24-hour and 30-day survival in combat casualties requiring MT.

Entities:  

Mesh:

Year:  2012        PMID: 22847102     DOI: 10.1097/TA.0b013e318260625a

Source DB:  PubMed          Journal:  J Trauma Acute Care Surg        ISSN: 2163-0755            Impact factor:   3.313


  17 in total

Review 1.  Acute blood loss during burn and soft tissue excisions: An observational study of blood product resuscitation practices and focused review.

Authors:  Heather F Pidcoke; Claire L Isbell; Maryanne C Herzig; Chriselda G Fedyk; Beverly S Schaffer; Kevin K Chung; Christopher E White; Steven E Wolf; Charles E Wade; Andrew P Cap
Journal:  J Trauma Acute Care Surg       Date:  2015-06       Impact factor: 3.313

Review 2.  The initial trauma center fluid management of penetrating injury: a systematic review.

Authors:  Nicole M Tapia; James Suliburk; Kenneth L Mattox
Journal:  Clin Orthop Relat Res       Date:  2013-12       Impact factor: 4.176

Review 3.  Massive haemorrhage in liver transplantation: Consequences, prediction and management.

Authors:  Stuart Cleland; Carlos Corredor; Jia Jia Ye; Coimbatore Srinivas; Stuart A McCluskey
Journal:  World J Transplant       Date:  2016-06-24

4.  Platelets stored at 4°C contribute to superior clot properties compared to current standard-of-care through fibrin-crosslinking.

Authors:  Prajeeda M Nair; Shaunak G Pandya; Shatha F Dallo; Kristin M Reddoch; Robbie K Montgomery; Heather F Pidcoke; Andrew P Cap; Anand K Ramasubramanian
Journal:  Br J Haematol       Date:  2017-06-04       Impact factor: 6.998

5.  Prehospital blood transfusions in pediatric trauma and nontrauma patients: a single-center review of safety and outcomes.

Authors:  Aodhnait S Fahy; Cornelius A Thiels; Stephanie F Polites; Maile Parker; Michael B Ishitani; Christopher R Moir; Kathleen Berns; James R Stubbs; Donald H Jenkins; Scott P Zietlow; Martin D Zielinski
Journal:  Pediatr Surg Int       Date:  2017-05-25       Impact factor: 1.827

6.  Multicenter observational prehospital resuscitation on helicopter study.

Authors:  John B Holcomb; Michael D Swartz; Stacia M DeSantis; Thomas J Greene; Erin E Fox; Deborah M Stein; Eileen M Bulger; Jeffrey D Kerby; Michael Goodman; Martin A Schreiber; Martin D Zielinski; Terence O'Keeffe; Kenji Inaba; Jeffrey S Tomasek; Jeanette M Podbielski; Savitri N Appana; Misung Yi; Charles E Wade
Journal:  J Trauma Acute Care Surg       Date:  2017-07       Impact factor: 3.313

7.  Integrated Compensatory Responses in a Human Model of Hemorrhage.

Authors:  Victor A Convertino; Carmen Hinojosa-Laborde; Gary W Muniz; Robert Carter
Journal:  J Vis Exp       Date:  2016-11-20       Impact factor: 1.355

8.  Resuscitate early with plasma and platelets or balance blood products gradually: findings from the PROMMTT study.

Authors:  Deborah J del Junco; John B Holcomb; Erin E Fox; Karen J Brasel; Herb A Phelan; Eileen M Bulger; Martin A Schreiber; Peter Muskat; Louis H Alarcon; Mitchell J Cohen; Bryan A Cotton; Charles E Wade; John G Myers; Mohammad H Rahbar
Journal:  J Trauma Acute Care Surg       Date:  2013-07       Impact factor: 3.313

9.  Primary hemostatic capacity of whole blood: a comprehensive analysis of pathogen reduction and refrigeration effects over time.

Authors:  Heather F Pidcoke; Steve J McFaul; Anand K Ramasubramanian; Bijaya K Parida; Alex G Mora; Chriselda G Fedyk; Krystal K Valdez-Delgado; Robbie K Montgomery; Kristin M Reddoch; Armando C Rodriguez; James K Aden; John A Jones; Ron S Bryant; Michael R Scherer; Heather L Reddy; Raymond P Goodrich; Andrew P Cap
Journal:  Transfusion       Date:  2013-01       Impact factor: 3.157

10.  The use of massive transfusion protocol for trauma and non-trauma patients in a civilian setting: what can be done better?

Authors:  Ramesh Wijaya; Hui Min Gloria Cheng; Chee Keong Chong
Journal:  Singapore Med J       Date:  2016-05       Impact factor: 1.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.